New hope for rare, Tough-to-Treat leukemia
NCT ID NCT05901974
Summary
This study is testing whether a combination of two drugs, venetoclax and azacitidine, can help people newly diagnosed with a rare and aggressive type of blood cancer called acute leukemia of ambiguous lineage. The goal is to see if this drug combo can put the cancer into remission and is safe for patients. Researchers are enrolling about 23 people aged 15 and older to participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affliated Hospital of Soochow University
RECRUITINGSuzhou, China
Contact
Conditions
Explore the condition pages connected to this study.